Full-Time

Vice President

Medical Affairs, General Medicine

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$300k - $500k/yr

Expert

Tarrytown, NY, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Regeneron Pharmaceuticals referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Board-certified physician with a strong preference for an individual who has expertise in multiple therapeutic areas, including leading teams in these areas.
  • At least 10 years of pharmaceutical experience, in either a clinical development role or in a medical affairs role. A preference will be for individuals with substantial medical affairs experience supporting global drug launches.
  • Experience leading teams with demonstration of successful collaborative efforts across various groups, including commercial and clinical development.
  • Ability to identify the most critical data points to appropriately drive innovative and effective solutions.
  • Knowledgeable in current and potential future trends, technology, policies, practices, and information of the competitive landscape of drug development and global health authority requirements for drug approval and successful commercialization.
Responsibilities
  • Lead and ensure successful execution of all relevant medical affairs programs and functions associated with General Medicine assets in clinical development, including the obesity program.
  • Lead the strategy and executional elements of phase IV (post-marketing) studies, and coordinate activities related to investigator-initiated/collaboration studies.
  • Collaborate with clinical development colleagues for the purpose of driving innovative development strategies, as well as being a collaborator with commercial colleagues.
  • Provide deep therapeutic area subject matter expertise to an expanding and advancing portfolio that will cover several molecules, therapeutic platforms, and disease areas.
  • Ensure that scientific rigor and innovation continue to be integrated into all medical affairs-related development and commercialization strategies.
  • Develop a world-class General Medicine medical affairs team; ensuring that our medical team is being challenged and developed to be ready to take on new roles and programs as the pipeline evolves.
  • Responsible for the timely planning and execution of medical affairs strategies addressing the development and/or commercialization needs for pipeline products.
  • Guide the medical affairs team to think broadly as it creates innovative medical affairs strategic options.
  • Provide robust career development plans for the team members to ensure they understand how they can continue to develop their careers.
  • Ensure that the best practices and learnings from the wide variety of general medicine programs are shared across the team to minimize 'reinventing the wheel' and to promote a vibrant collaborative environment.
  • Serve as principal spokesperson for the medical affairs function on highly significant matters pertaining to the General Medicine GMF.
Desired Qualifications
  • Experience in rare diseases would be a valuable attribute.
  • Excels at bringing the creative ideas of others forward and knows how to manage and cultivate the creative process of others; encourages diverse ideas and open conversations.
  • Is aware of and provides challenging stretch assignments that are aligned with each team member’s career aspirations; hold frequent feedback and development discussions.
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its efforts. Regeneron generates revenue by selling its approved medicines and through licensing agreements, sharing costs and profits with partners in co-development projects. Unlike many competitors, Regeneron emphasizes strong research capabilities and strategic partnerships to stay ahead in the biotechnology field. The company's goal is to improve patient outcomes by delivering effective treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Dupixent's approval for CSU opens a new market segment in the US.
  • $3.6 billion Tarrytown expansion boosts research capabilities and local economy.
  • Partnership with Fujifilm enhances manufacturing capacity for biologics.

What critics are saying

  • Tarrytown expansion poses financial risk if ROI is not realized.
  • Dependency on Fujifilm for manufacturing may lead to operational risks.
  • Regulatory setbacks, like Dupixent's initial rejection, can impact market entry.

What makes Regeneron Pharmaceuticals unique

  • Regeneron specializes in life-transforming medicines for serious diseases.
  • The company leverages proprietary technologies for innovative drug development.
  • Regeneron collaborates with academic and research institutions to enhance R&D efforts.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

Ophthalmology Times
Apr 28th, 2025
Regeneron to highlight real-world efficacy of aflibercept 8 mg (EYLEA HD) in wAMD, DME, and DR

Regeneron has announced the upcoming presentation of 27 abstracts, including 8 oral presentations on aflibercept injection 8 mg (EYLEA HD) in wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.

Pharma Journalist
Apr 24th, 2025
Regeneron Invests in Expanding Biologic Medicine Manufacturing

Regeneron continues to invest heavily in its New York State operations, where an approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing and support facilities.

PharmiWeb
Apr 24th, 2025
Dupixent Approved In The Us As The First New Targeted Therapy In Over A Decade For Chronic Spontaneous Urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks

Texas Border Business
Apr 23rd, 2025
America's Manufacturing Power Surges as Global Giants Invest Billions

Additionally, Regeneron is investing approximately $3.6 billion to expand its Tarrytown, New York facility, aiming to double its manufacturing capabilities nearly.

Pharmaceutical Technology
Apr 22nd, 2025
Regeneron partners with Fujifilm to broaden manufacturing capacity

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity.